Maintenance Notice (10:30 PM January 4 - 8:00 AM January 5, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197 | Notice of Discontinuing the Use of Password-Protected Compressed Files | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 17902-23-7 | 產品號碼: F0635
5-Fluoro-1-(tetrahydro-2-furfuryl)uracil
×
![]()
×
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
產品規格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(with Total Nitrogen) | min. 98.0 % |
| Melting point | 167.0 to 171.0 °C |
| NMR | confirm to structure |
性質
| 熔點 | 169 °C |
GHS
| 圖形表示 |
|
| 信號詞 | Danger |
| 危險性說明 | H300 : Fatal if swallowed. H373 : May cause damage to organs through prolonged or repeated exposure. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P314 : Get medical advice/ attention if you feel unwell. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
相關法規
| RTECS # | YR0450000 |
運輸資料
| UN編號 | UN2811 |
| 類別 | 6.1 |
| 包裝類別 | II |
| HS編碼* | 2940.00-000 |
Application
Tegafur: A Prodrug of an Active Antitumor 5-FU
Tegafur is a prodrug that is metabolized by cytochrome P 450 to an active antitumor 5-FU [F0151]. Tegafur is often used as combined agents such as UFT (tegafur and uracil [U0013] at a molar ratio of 1:4) or S-1 (tegafur, gimeracil [C2243] and potassium oxonate [O0164] at a molar ratio of 1:0.4:1) to increase the plasma and tumor 5-FU concentrations. Determination of the combined agents in plasma is important to evaluate the safety and efficacy of them. (The product is for research purpose only.)
References
- Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents
- Bioactivation of Tegafur to 5-fluorouracil is catalyzed by cytochrome P 450 2A6 in human liver microsomes in vitro
- Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
- Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review
- Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry
- Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry
考研文獻
文章/手冊
TCIMail
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。